

ANDREW M. CUOMO Governor **HOWARD A. ZUCKER, M.D., J.D.**Acting Commissioner

SALLY DRESLIN, M.S., R.N.Executive Deputy Commissioner

UPDATED Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective August 6, 2015, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- Aggrenox, Zyvox, and Focalin XR 20mg will be <u>added</u> to the program.
- Exforge and Carac will be <u>removed</u> from the program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

List of Brand Name Drugs included in this program* (Updated 7/23/2015):

Adderall XR	Gabitril 2mg, 4mg	Tegretol suspension
Aggrenox	Hepsera	Tegretol XR
Aldara	Intuniv	Tobradex suspension
Alphagan P 0.15%	Kadian	TOBI
Astepro	Lidoderm	Tricor
Bactroban Cream	Mepron	Trileptal suspension
Baraclude	Metrogel	Trilipix
Catapres-TTS	Myfortic	Trizivir
Cellcept suspension	Niaspan	Valcyte
Combivir	Patanase	Wellbutrin
Depakote sprinkle	Protopic	Xeloda
Diastat	Pulmicort Respules	Zyvox
Epivir HBV tablet	Rapamune tablet	
Focalin XR 5mg, 10mg,	Soriatane	
15mg, 20mg 30mg,40mg		

^{*}List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.